Development of an In Vitro Dissolution Technique to Understand the Clinical Based

Information

  • Research Project
  • 8904333
  • ApplicationId
    8904333
  • Core Project Number
    U01FD004953
  • Full Project Number
    5U01FD004953-02
  • Serial Number
    004953
  • FOA Number
    RFA-FD-13-014
  • Sub Project Id
  • Project Start Date
    9/15/2013 - 11 years ago
  • Project End Date
    10/31/2016 - 8 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/2014 - 10 years ago
  • Budget End Date
    10/31/2016 - 8 years ago
  • Fiscal Year
    2014
  • Support Year
    02
  • Suffix
  • Award Notice Date
    9/8/2014 - 10 years ago
Organizations

Development of an In Vitro Dissolution Technique to Understand the Clinical Based

There are many challenges in predicting the fate of inhaled particles in the lung and to determine the influence of formulation and device factors on the efficacy and safety of orally inhaled drug products. In this proposal, we seek to develop a in vitro dissolution system, which can predict clinically related endpoints such as the rate and extent of drug absorption measured by pharmacokinetics. The major research objective is to develop a robust dissolution system which takes into account the composition and limited lung fluid available for dissolution, influence of local dosimetry differences between formulations and devices and how these factors influence dissolution and permeability of drugs for delivery to the respiratory tract. A greater understanding and IVIVC mathematical modeling of the relationship between the physico---chemical properties of drugs, local dissolution effects and permeability will provide the necessary science and tools to enable greater control of product safety, efficacy, potency, quality and functionality. The exploration into the relationship between dissolution, permeability and pharmacokinetics will enable the FDA to direct both branded and generic industries to define quality and functionality of orally inhaled drug products.

IC Name
FOOD AND DRUG ADMINISTRATION
  • Activity
    U01
  • Administering IC
    FD
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    44999
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    FDA:44999\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZFD1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF BATH
  • Organization Department
  • Organization DUNS
    424400661
  • Organization City
    BATH
  • Organization State
  • Organization Country
    UNITED KINGDOM
  • Organization Zip Code
    BA2 7AY
  • Organization District
    UNITED KINGDOM